Results 91 to 100 of about 15,808 (143)

Screening the Antibiotic Activity of Cave Actinobacteria Against Multidrug‐Resistant Strains of Pseudomonas aeruginosa and Methicillin‐Resistant Staphylococcus aureus

open access: yesInternational Journal of Microbiology, Volume 2026, Issue 1, 2026.
Many antibiotics originate from soil‐inhabiting Actinobacteria, especially from the diverse genus Streptomyces. However, the emergence of antibiotic resistance poses a significant global challenge to treating infectious diseases. Therefore, the search for Actinobacteria, particularly from less‐explored environments, as potential sources of novel ...
Rajani Balkrishna Rao   +6 more
wiley   +1 more source

Analysis of patients with diabetes and complicated intra-abdominal infection or complicated urinary tract infection in phase 3 trials of ceftolozane/tazobactam

open access: yesBMC Infectious Diseases, 2017
Background Diabetes mellitus and hyperglycemia are associated with increased susceptibility to bacterial infections and poor treatment outcomes. This post hoc evaluation of the treatment of complicated intra-abdominal infections (cIAI) and complicated ...
Myra W. Popejoy   +2 more
doaj   +1 more source

In vitro susceptibility of Burkholderia cepacia complex isolated from cystic fibrosis patients to ceftazidime-avibactam and ceftolozane-tazobactam

open access: yes, 2018
We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012.
Peeters, Charlotte   +16 more
core   +1 more source

In vitro susceptibility profile of BLEES-positive Enterobacteriaceae isolated from clinical specimens to ceftolozane/tazobactam [PDF]

open access: yes, 2019
Las Enterobacterias son un grupo grande y heterogéneo de bacterias gramnegativas, las cuales se caracterizan por su capacidad de producir infecciones en pacientes inmunocompetentes e inmunosuprimidos tanto de la comunidad como en el ambiente ...
Valderrama Rodríguez, Cristian Camilo
core   +1 more source

A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam

open access: yesMediterranean Journal of Infection, Microbes and Antimicrobials, 2019
Ceftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with ...
Kıvanç ŞEREFHANOĞLU
doaj   +1 more source

Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. [PDF]

open access: yes, 2014
We compared the dynamics and mechanisms of resistance development to ceftazidime, meropenem, ciprofloxacin, and ceftolozane-tazobactam in wild-type (PAO1) and mutator (PAOMS, ΔmutS) P. aeruginosa.
Moyà, Bartolomé   +7 more
core   +1 more source

Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency

open access: yesRespiratory Medicine Case Reports, 2018
We report the successful use of ceftolozane/tazobactam (C/T) to treat a pulmonary exacerbation in a 35 year old female, post lung transplant, with cystic fibrosis (CF), malnutrition, chronic kidney disease, and multi-drug resistant Pseudomonas aeruginosa
Katie Stokem   +4 more
doaj   +1 more source

Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia

open access: yes, 2020
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Patients admitted to hospitals are at risk of developing nosocomial infections. These types of infections typically occur in immune compromised patients.
Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A
core  

Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.

open access: yes, 2018
Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.
Brian D. Johnston (580892)   +2 more
core   +1 more source

Comparison of ceftolozane–tazobactam and ceftazidime–avibactam for the treatment of infections caused by drug-resistant Pseudomonas aeruginosa: an updated systematic review and meta-analysis based on adjusted data from observational studies

open access: yesInternational Journal of Infectious Diseases
Background: Clinical guidelines recommend two novel β-lactam/β-lactamase inhibitor combinations—ceftolozane–tazobactam and ceftazidime–avibactam—as first-line therapies for drug-resistant Pseudomonas aeruginosa infections.
Pengfei Li   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy